Bellicum to be added to the nasdaq biotechnology index
Houston--(business wire)--bellicum pharmaceuticals, inc. (nasdaq:blcm), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the company has been selected for inclusion in the nasdaq biotechnology index® (nasdaq: nbi). this addition will be effective prior to market open on monday, december 21, 2015. the nasdaq biotechnology index is designed to track the performance of a set of securities listed on the nasdaq stock market® (nasdaq®) that are classified as either biotechnology or pharmaceutical according to the industry classification benchmark (icb). the nasdaq biotechnology index is calculated under a modified capitalization-weighted methodology and ranked on an annual basis. all securities in the nasdaq biotechnology index are listed on the nasdaq global market or the nasdaq global select market, and meet minimum market value and share volume requirements among other criteria. for more information about the nasdaq biotechnology index, including eligibility criteria, visit www.nasdaq.com. about bellicum pharmaceuticals bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. bellicum is using its proprietary chemical induction of dimerization (cid) technology platform to engineer and control components of the immune system. bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct), and car-t and tcr cell therapies. more information can be found at www.bellicum.com.
BLCM Ratings Summary
BLCM Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission